- Tools for Investors
- Stock News
- Investing Ideas
- Econ & Policy
- Personal Finance
Amgen (NASDAQ:AMGN): Closing price $84.32
On Wednesday, Amgen announced top-line results of the Phase 3 Aranesp (darbepoetin alfa) RED-HF (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial, which was begun in 2006. A total number of 2,278 patients suffering from symptomatic systolic heart failure and anemia (hemoglobin levels ranging from 9.0-12.0 g/dL) were randomized to receive either treatment with Aranesp to reach a target hemoglobin of a minimum of 13.0 g/dL (not to exceed 14.5 g/dL), or placebo. The evaluation failed to meet its primary endpoint of reducing the composite endpoint of time to death from any cause or first hospital admission for worsening heart failure.
Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
There's always a bull market in some sector! Find the best opportunities in commodities.